Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy

被引：0
|
作者：
Tada, K. [1 ,2 ]
Shoji, H. [3 ]
Kitano, S. [4 ]
Nishimura, T. [5 ]
Shimada, Y. [3 ]
Nagashima, K. [6 ]
Ito, A. [7 ]
Honma, Y. [3 ]
Iwasa, S. [3 ]
Okita, N. [3 ]
Takashima, A. [3 ]
Kato, K. [3 ]
Yamada, Y. [3 ]
Katayama, N. [8 ]
Boku, N. [3 ]
Heike, Y. [1 ]
Hamaguchi, T. [3 ]
机构：
[1] St Lukes Int Hosp, Immunotherapy & Cell Therapy Serv, Tokyo, Japan
[2] Natl Canc Ctr, Div Canc Immunotherapy, Tokyo, Japan
[3] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan
[4] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[5] Tokyo Jikei Med Univ, Gastrointestinal Med Div, Tokyo, Japan
[6] Chiba Univ, Dept Global Clin Res, Chiba, Japan
[7] Natl Canc Ctr, Hematopoietci Stem Cell Transplant Div, Tokyo, Japan
[8] Mie Univ, Dept Hematol & Oncol, Tsu, Mie 514, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30240-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
406
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [21] Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer
    Sorbye, Halfdan
    Berglund, Ake
    Tveit, Kjell Magne
    Ogreid, Dagfinn
    Wanderas, Eva Hoff
    Wentzel-Larsen, Tore
    Dahl, Olav
    Glimelius, Bengt
    ACTA ONCOLOGICA, 2007, 46 (07) : 982 - 988
  • [22] Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer
    Beatty, Gregory L.
    Giantonio, Bruce J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (05) : 683 - 688
  • [23] Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy
    Ryota Nakanishi
    Eiji Oki
    Hirofumi Hasuda
    Eiki Sano
    Yu Miyashita
    Akihiro Sakai
    Naomichi Koga
    Naotaka Kuriyama
    Kentaro Nonaka
    Yoshiaki Fujimoto
    Tomoko Jogo
    Kentaro Hokonohara
    Qingjiang Hu
    Yuichi Hisamatsu
    Koji Ando
    Yasue Kimura
    Tomoharu Yoshizumi
    Masaki Mori
    Annals of Surgical Oncology, 2021, 28 : 2975 - 2985
  • [24] TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy
    Matsusaka, Satoshi
    Zhang, Wu
    Cao, Shu
    Hanna, Diana L.
    Sunakawa, Yu
    Sebio, Ana
    Ueno, Masashi
    Yang, Dongyun
    Ning, Yan
    Parekh, Anish
    Okazaki, Satoshi
    Berger, Martin D.
    Ichikawa, Wataru
    Mizunuma, Nobuyuki
    Lenz, Heinz-Josef
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (06) : 1405 - 1411
  • [25] First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
    Ree, Anne Hansen
    Benth, Jurate Saltyte
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Bjornetro, Tonje
    Nilsen, Hilde L.
    Berg, Jens P.
    Flatmark, Kjersti
    Meltzer, Sebastian
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1921 - 1928
  • [26] Association of XPD Asp312Asn polymorphism and response to oxaliplatin-based first-line chemotherapy and survival in patients with metastatic colorectal cancer
    Liu, Zhuo
    Kong, Jiangyin
    Kong, Yuanyuan
    Cai, Feng
    Xu, Xiaocheng
    Liu, Jun
    Wang, Shihua
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (11): : 1459 - 1468
  • [27] Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
    Kjersem, J. B.
    Ikdahl, T.
    Lingjaerde, O. C.
    Guren, T.
    Tveit, K. M.
    Kure, E. H.
    MOLECULAR ONCOLOGY, 2014, 8 (01) : 59 - 67
  • [28] Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases
    Giannini, Valentina
    Pusceddu, Laura
    Defeudis, Arianna
    Nicoletti, Giulia
    Cappello, Giovanni
    Mazzetti, Simone
    Sartore-Bianchi, Andrea
    Siena, Salvatore
    Vanzulli, Angelo
    Rizzetto, Francesco
    Fenocchio, Elisabetta
    Lazzari, Luca
    Bardelli, Alberto
    Marsoni, Silvia
    Regge, Daniele
    CANCERS, 2022, 14 (01)
  • [29] Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study
    Marschner, Norbert
    Arnold, Dirk
    Engel, Erik
    Hutzschenreuter, Ulrich
    Rauh, Jacqueline
    Freier, Werner
    Hartmann, Holger
    Frank, Melanie
    Jaenicke, Martina
    CLINICAL EPIDEMIOLOGY, 2015, 7 : 295 - 303
  • [30] Oxaliplatin,Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
    Bing Han Ruihua Xu Yanxia Shi Huiyan Luo Xiaojuan Xiang Yuhong Li Li Zhang Tongyu Lin Youjian HeDepartment of Medical Oncology
    Chinese Journal of Clinical Oncology, 2007, (06) : 397 - 400
12345